NCT03877796 Clinical Pre-screening Protocol for Ovarian Cancer
| NCT ID | NCT03877796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Allarity Therapeutics |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2019-04-11 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2019-04-11 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Eligibility Criteria
Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03877796 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03877796 currently recruiting?
Yes, NCT03877796 is actively recruiting participants. Contact the research team at KathleenMoore@ouhealth.com for enrollment information.
Where is the NCT03877796 trial being conducted?
This trial is being conducted at Tampa, United States, Atlanta, United States, Albuquerque, United States, New York, United States and 5 additional locations.
Who is sponsoring the NCT03877796 clinical trial?
NCT03877796 is sponsored by Allarity Therapeutics. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.